EP Patent

EP1609799A1 — Heteroaryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same

Assigned to Taisho Pharmaceutical Co Ltd · Expires 2005-12-28 · 20y expired

What this patent protects

There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a p…

USPTO Abstract

There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
EP1609799A1
Jurisdiction
EP
Classification
—
Expires
2005-12-28
Drug substance claim
No
Drug product claim
No
Assignee
Taisho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.